KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Investing Activities (2018 - 2025)

Adaptive Biotechnologies' Cash from Investing Activities history spans 8 years, with the latest figure at -$8.3 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 137.31% year-over-year to -$8.3 million; the TTM value through Dec 2025 reached $37.9 million, down 51.22%, while the annual FY2025 figure was $37.9 million, 51.22% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$8.3 million at Adaptive Biotechnologies, down from $17.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $93.8 million in Q1 2021 and bottomed at -$97.5 million in Q4 2022.
  • The 5-year median for Cash from Investing Activities is $23.8 million (2024), against an average of $21.5 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 245.13% in 2022 before it surged 686.41% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $67.2 million in 2021, then crashed by 245.13% to -$97.5 million in 2022, then surged by 103.29% to $3.2 million in 2023, then skyrocketed by 589.71% to $22.1 million in 2024, then tumbled by 137.31% to -$8.3 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Cash from Investing Activities are -$8.3 million (Q4 2025), $17.3 million (Q3 2025), and $3.3 million (Q2 2025).